Project ID: D2013-47
Novelty: Three categories of drug-like molecules that have been identified to promote bone and cartilage formation from stem cells.
Value Proposition: Osteoporosis and Osteoarthritis are complex musculoskeletal diseases that are prevalent in the aging population. Worldwide, Osteoporosis is estimated to affect approximately 200 million women and Osteoarthritis affects more than 151 million people currently. Despite large number of patients and active research in these areas, there is no technology to prevent or modify osteoarthritis. Regarding osteoporosis, current technology on the market can reduce recurrent fracture risk only 65% of the time and is associated with significant risks including avascular necrosis of the tempormandibular joints, subtrochanteric femur fractures and malignant tumors of bone. There is a huge need to develop new and improved therapeutics for effective treatment of these musculoskeletal diseases.
To this end, researchers at the University of Toledo have devised new compounds that induce bone and cartilage formation that can serve as medications for prevention and treatment of osteoporosis, osteoarthritis, metabolic bone disorders, fracture management and other musculoskeletal disorders. These compounds can be administered either directly to patients or used in vitro to treat stem cells which are then administered to patients. The capabilities of this invention will greatly impact the current treatment of these musculoskeletal diseases.
Applications: Development of medications against osteoporosis, osteoarthritis and other musculoskeletal diseases.
IP status: Patent Pending-US20240166613A1
Related Publications:
Kim DH, Puri N, Sodhi K, Falck JR, Abraham NG, Shapiro J, Schwartzman ML. J Lipid Res. 2013 Mar; 54(3):786-93.